MC3 Recorded Education Series: SSRIs: The Essentials
To begin this activity, click Enroll. Once logged in, learners can access educational content, assessments, and evaluations. Learners who successfully complete the activity will be able to print a certificate.
Release Date:
Fri, 5/3/19
Termination Date:
Tue, 12/31/19
Credits:
1
Description:
This presentation will teach clinicians to assess and consider risk of treating with SSRI medications as well as the risks of not treating with SSRI medications. Detailed information about specific medicines will be provided to allow clinicians to improve the precision of their medical recommendations.
Educational Objectives:
Through this education activity, participants will enhance their comfort discussing, initiating, and following the course of SSRI medications for youth with depression. There will be subsequent improvement in outcomes for the patient, parents and providers.
Target Audience:
This activity is appropriate for House Officers, Medical Students, Nurse Practitioners, Nurses, Other Healthcare Professionals, Physician Assistants, Physicians, Social Workers in the fields of Adolescent Medicine, Family Medicine, Pediatrics, Primary Care, Psychiatry, Psychology, Sleep Medicine, Social Work.
Accreditation and Credit Designation:
Accreditation and Credit Designation
The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Michigan Medical School designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: 05/03/19
Termination Date: 04/30/22
Additional Info:
Presenter:
Richard Dopp, MD
Educational Planner
Richard Dopp, MD
Educational Co-Planners
Erin Hughes-Krieger, MSW
Anne Kramer, MSW
Financial Disclosures:
There are no relevant financial relationships with ACCME-defined commercial interests to disclose for this activity.
References:
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: Author.
The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks.
March J1, Silva S, Vitiello B; TADS Team.
J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1393-403.
Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
Kennard B1, Silva S, Vitiello B, Curry J, Kratochvil C, Simons A, Hughes J, Feeny N, Weller E, Sweeney M, Reinecke M, Pathak S, Ginsburg G, Emslie G, March J; TADS Team.
J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1404-11.
Richard Dopp, MD
Educational Planner
Richard Dopp, MD
Educational Co-Planners
Erin Hughes-Krieger, MSW
Anne Kramer, MSW
Financial Disclosures:
There are no relevant financial relationships with ACCME-defined commercial interests to disclose for this activity.
References:
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: Author.
The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks.
March J1, Silva S, Vitiello B; TADS Team.
J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1393-403.
Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
Kennard B1, Silva S, Vitiello B, Curry J, Kratochvil C, Simons A, Hughes J, Feeny N, Weller E, Sweeney M, Reinecke M, Pathak S, Ginsburg G, Emslie G, March J; TADS Team.
J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1404-11.
Credits available:
AMA PRA Category 1: 1.00
Participation: 1.00
